Cargando…

DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation

Enhancer elements are a key regulatory feature of many important genes. Several general features including the presence of specific histone modifications are used to demarcate potentially active enhancers. Here we reveal that putative enhancers marked with H3 lysine 79 (H3K79) di or trimethylation (...

Descripción completa

Detalles Bibliográficos
Autores principales: Godfrey, Laura, Crump, Nicholas T., Thorne, Ross, Lau, I-Jun, Repapi, Emmanouela, Dimou, Dimitra, Smith, Alastair L., Harman, Joe R., Telenius, Jelena M., Oudelaar, A. Marieke, Downes, Damien J., Vyas, Paresh, Hughes, Jim R., Milne, Thomas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594956/
https://www.ncbi.nlm.nih.gov/pubmed/31243293
http://dx.doi.org/10.1038/s41467-019-10844-3
_version_ 1783430321420632064
author Godfrey, Laura
Crump, Nicholas T.
Thorne, Ross
Lau, I-Jun
Repapi, Emmanouela
Dimou, Dimitra
Smith, Alastair L.
Harman, Joe R.
Telenius, Jelena M.
Oudelaar, A. Marieke
Downes, Damien J.
Vyas, Paresh
Hughes, Jim R.
Milne, Thomas A.
author_facet Godfrey, Laura
Crump, Nicholas T.
Thorne, Ross
Lau, I-Jun
Repapi, Emmanouela
Dimou, Dimitra
Smith, Alastair L.
Harman, Joe R.
Telenius, Jelena M.
Oudelaar, A. Marieke
Downes, Damien J.
Vyas, Paresh
Hughes, Jim R.
Milne, Thomas A.
author_sort Godfrey, Laura
collection PubMed
description Enhancer elements are a key regulatory feature of many important genes. Several general features including the presence of specific histone modifications are used to demarcate potentially active enhancers. Here we reveal that putative enhancers marked with H3 lysine 79 (H3K79) di or trimethylation (me2/3) (which we name H3K79me2/3 enhancer elements or KEEs) can be found in multiple cell types. Mixed lineage leukemia gene (MLL) rearrangements (MLL-r) such as MLL-AF4 are a major cause of incurable acute lymphoblastic leukemias (ALL). Using the DOT1L inhibitor EPZ-5676 in MLL-AF4 leukemia cells, we show that H3K79me2/3 is required for maintaining chromatin accessibility, histone acetylation and transcription factor binding specifically at KEEs but not non-KEE enhancers. We go on to show that H3K79me2/3 is essential for maintaining enhancer-promoter interactions at a subset of KEEs. Together, these data implicate H3K79me2/3 as having a functional role at a subset of active enhancers in MLL-AF4 leukemia cells.
format Online
Article
Text
id pubmed-6594956
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-65949562019-06-28 DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation Godfrey, Laura Crump, Nicholas T. Thorne, Ross Lau, I-Jun Repapi, Emmanouela Dimou, Dimitra Smith, Alastair L. Harman, Joe R. Telenius, Jelena M. Oudelaar, A. Marieke Downes, Damien J. Vyas, Paresh Hughes, Jim R. Milne, Thomas A. Nat Commun Article Enhancer elements are a key regulatory feature of many important genes. Several general features including the presence of specific histone modifications are used to demarcate potentially active enhancers. Here we reveal that putative enhancers marked with H3 lysine 79 (H3K79) di or trimethylation (me2/3) (which we name H3K79me2/3 enhancer elements or KEEs) can be found in multiple cell types. Mixed lineage leukemia gene (MLL) rearrangements (MLL-r) such as MLL-AF4 are a major cause of incurable acute lymphoblastic leukemias (ALL). Using the DOT1L inhibitor EPZ-5676 in MLL-AF4 leukemia cells, we show that H3K79me2/3 is required for maintaining chromatin accessibility, histone acetylation and transcription factor binding specifically at KEEs but not non-KEE enhancers. We go on to show that H3K79me2/3 is essential for maintaining enhancer-promoter interactions at a subset of KEEs. Together, these data implicate H3K79me2/3 as having a functional role at a subset of active enhancers in MLL-AF4 leukemia cells. Nature Publishing Group UK 2019-06-26 /pmc/articles/PMC6594956/ /pubmed/31243293 http://dx.doi.org/10.1038/s41467-019-10844-3 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Godfrey, Laura
Crump, Nicholas T.
Thorne, Ross
Lau, I-Jun
Repapi, Emmanouela
Dimou, Dimitra
Smith, Alastair L.
Harman, Joe R.
Telenius, Jelena M.
Oudelaar, A. Marieke
Downes, Damien J.
Vyas, Paresh
Hughes, Jim R.
Milne, Thomas A.
DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation
title DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation
title_full DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation
title_fullStr DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation
title_full_unstemmed DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation
title_short DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation
title_sort dot1l inhibition reveals a distinct subset of enhancers dependent on h3k79 methylation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594956/
https://www.ncbi.nlm.nih.gov/pubmed/31243293
http://dx.doi.org/10.1038/s41467-019-10844-3
work_keys_str_mv AT godfreylaura dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation
AT crumpnicholast dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation
AT thorneross dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation
AT lauijun dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation
AT repapiemmanouela dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation
AT dimoudimitra dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation
AT smithalastairl dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation
AT harmanjoer dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation
AT teleniusjelenam dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation
AT oudelaaramarieke dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation
AT downesdamienj dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation
AT vyasparesh dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation
AT hughesjimr dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation
AT milnethomasa dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation